MannKind Corporation (MNKD)

Aerovate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	301.74	285.5	198.96	99.77	75.44	65.14
Revenue	301.74	285.5	198.96	99.77	75.44	65.14
Revenue Growth (YoY)	21.49%	43.50%	99.42%	32.25%	15.81%	3.34%
Cost of Revenue	75.71	76.6	62.77	57.5	38.86	24.64
Gross Profit	226.03	208.9	136.19	42.27	36.59	40.5
Selling, General & Admin	104.52	94.33	94.31	91.47	77.42	59.04
Research & Development	48.76	45.89	31.28	19.72	12.31	6.25
Operating Expenses	153.29	140.22	125.6	111.19	89.73	65.29
Operating Income	72.74	68.68	10.59	-68.92	-53.14	-24.79
Interest Expense	-32.66	-37.98	-25.16	-24.77	-16.58	-9.47
Interest & Investment Income	9.79	12.62	6.15	2.51	0.11	0.17
Currency Exchange Gain (Loss)	-5.89	3.91	-1.92	4.81	6.57	-8.01
Other Non Operating Income (Expenses)	0.03	0.03	0.12	-0.1	-0.58	-1.87
EBT Excluding Unusual Items	44.01	47.25	-10.21	-86.47	-63.62	-43.96
Gain (Loss) on Sale of Investments	-	-1.55	-0.17	-0.93	-	-
Asset Writedown	-	-	-	-	-0.11	-
Other Unusual Items	-8.14	-15.19	-	-	-17.2	-0.26
Pretax Income	35.87	30.52	-10.38	-87.4	-80.93	-57.46
Income Tax Expense	3.07	2.93	1.56	-	-	-0.22
Net Income	32.8	27.59	-11.94	-87.4	-80.93	-57.24
Net Income to Common	32.8	27.59	-11.94	-87.4	-80.93	-57.24
Shares Outstanding (Basic)	291	274	267	257	249	223
Shares Outstanding (Diluted)	300	284	267	257	249	223
Shares Change (YoY)	9.50%	6.30%	3.86%	3.15%	11.98%	13.80%
EPS (Basic)	0.11	0.10	-0.04	-0.34	-0.32	-0.26
EPS (Diluted)	0.11	0.10	-0.04	-0.34	-0.32	-0.26
Free Cash Flow	28.79	32.82	-8.35	-88.27	-73.18	-28.93
Free Cash Flow Per Share	0.10	0.12	-0.03	-0.34	-0.29	-0.13
Gross Margin	74.91%	73.17%	68.45%	42.37%	48.49%	62.18%
Operating Margin	24.11%	24.06%	5.33%	-69.08%	-70.44%	-38.05%
Profit Margin	10.87%	9.66%	-6.00%	-87.60%	-107.27%	-87.87%
Free Cash Flow Margin	9.54%	11.49%	-4.20%	-88.47%	-97.00%	-44.41%
EBITDA	81.21	76.05	15.13	-65.6	-51.16	-22.9
EBITDA Margin	26.91%	26.64%	7.60%	-65.75%	-67.81%	-35.16%
D&A For EBITDA	8.47	7.37	4.54	3.33	1.99	1.88
EBIT	72.74	68.68	10.59	-68.92	-53.14	-24.79
EBIT Margin	24.11%	24.06%	5.33%	-69.08%	-70.44%	-38.05%
Effective Tax Rate	8.57%	9.60%	-	-	-	-
Revenue as Reported	301.74	285.5	198.96	99.77	75.44	65.14

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q